Latest Industry Insights
Industry Insight
A New Year in Proteomics
2020 was an important year for proteomics. The COVID-19 global pandemic cast a spotlight on the field's clinical utility in the fight against a public health crisis, from which there are many lessons to be drawn that will undoubtedly influence the landscape of the field for years to come. Technology Networks spoke with Rohan Thakur, executive vice president of Life Sciences Mass Spectrometry at Bruker Daltonics, to discuss the current state-of-play in proteomics.
Industry Insight
Exploring the Relationship Between the Microbiome, Precision Medicine and Cancer
The trillions of microbes contained in the human body are a key element of a personalized approach to treatment; the microbiome influences endocrinology, physiology, and even neurology, and has a crucial role in disease progression. An area in which interest is growing particularly quickly is oncology. To further investigate the link between the microbiome and cancer, we take a closer look at the current landscape of melanoma research.
Industry Insight
The Link Between Cancer and Metabolic Dysfunction
SynDevRx is working to address the unmet medical need in the field of metabo-oncology by developing treatments for cancer patients who are overweight or have systemic metabolic dysfunction. Technology Networks recently spoke with SynDevRx's Jim Shanahan, to explore the impact of metabolic dysfunction on treatment outcomes and learn more about the company’s lead compound SDX-7320.
Industry Insight
Exploring the Challenges and Opportunities of Harvesting CTCs
In a recent study, CTCs were harvested to investigate the causes of brain metastasis in non-small cell lung cancer patients. We spoke to Andrew Newland, CEO, ANGLE, to learn more about the study, the challenges of harvesting CTCs and how the Parsortix system overcomes some of these challenges.
Industry Insight
Pushing the Boundaries of Translational Molecular Imaging
Professor Ron Heeren recently embarked on a study to bring together the spatial molecular information that is provided by MALDI-MSI with the microproteomic characterization generated by LC-MS on the same tissue specimen, on a single instrument. Heeren and colleagues were successful in this feat. Their work is published in the journal Proteomics and forms the basis of this interview.
Industry Insight
Engineering Innovative CAR T-Cell Therapy Candidates for Cancer
Technology Networks recently had the pleasure of speaking with Celyad Oncology’s CEO Filippo Petti. In this interview, Petti discusses key immunotherapy advances, highlights the two main CAR T-cell therapy approaches and elaborates on the company’s “off-the-shelf” CAR T cells.
Industry Insight
Using Organoids in the Study of Infectious Diseases
By providing greater physiologic relevance and a species- or patient-specific test platform, organoids overcome many limitations of conventional 2D cultures and even live-animal disease models.
Industry Insight
Progress in Companion Diagnostic Development for Low-Grade Glioma
To learn about the benefits of accelerating turnaround times for genomic testing and the importance of partnering with pharma companies to develop companion diagnostics, Technology Networks spoke with Luca Quagliata, PhD, BCMAS, global director of medical affairs for Thermo Fisher Scientific.
Industry Insight
Breaking Down Barriers in Proteomic-Based Drug Discovery
SomaLogic recently announced an agreement with the biopharmaceutical company Amgen that aims to advance Amgen's drug discovery and development programs through comprehensive proteomic profiling. We spoke with Roy Smythe to discover what barriers have been holding proteome analysis back, and how the collaboration with Amgen aims to change the landscape of drug discovery.
Industry Insight
Biomaterial-Based Vaccine That Sits Under the Skin Shows Promise Against SARS-CoV-2
A team of multidisciplinary scientists – including bioengineers, materials-scientists and immunologists – at the Wyss Institute has created a novel infection vaccine platform know as OmniVax. Technology Networks spoke with Lead Senior Staff Scientist Ed Doherty from the Wyss Institute for Biologically Inspired Engineering at Harvard University, to learn more.
Advertisement